MATTHEW W. STROBECK, PH.D. - Corporate Board Profile

Accelerate Diagnostics, Inc

Filing Date	Source Excerpt
2012-11-13	Matthew W. Strobeck, Ph.D. has served as a Director of the Company since July 7, 2012. ... Jack Schuler and Matthew W. Strobeck, Ph.D., each independent directors, serve as members of our Audit Committee. ... The table below sets forth the compensation of our directors for serving as our directors for the fiscal year ended July 31, 2012: ... Matthew W. Strobeck, Ph.D. fees earned or paid in cash: —, non-equity stock awards: —, option awards: —, total: —.
2013-11-05	The Board maintains a standing Audit Committee comprised of Mr. ten Brink (Chairman), Mr. Schuler and Dr. Strobeck.
2014-04-15	Matthew W. Strobeck, Ph.D. 41 Director Matthew W. Strobeck, Ph.D. 212,542 Includes annual award of option to purchase 44,670 shares of common stock at an exercise price of $6.48 per share, which vests in 12 equal monthly installments with the first installment vesting on May 3, 2013.
2015-04-08	Matthew W. Strobeck, Ph.D. has served as a Director of the Company since July 7, 2012. Dr. Strobeck is currently the Managing Partner of Birchview Capital. Dr. Strobeck was a Partner and Member of the Management Committee and Advisory Board of Westfield Capital Management from 2008 until 2011, having served as a member of the investment team, specializing in healthcare and life sciences, from May 2003 to June 2008. Dr. Strobeck received his B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, a S.M. from the Harvard University/MIT Health Sciences Technology Program, and a S.M. from the MIT Sloan School of Management.
2016-04-01	Matthew W. Strobeck, Ph.D. 43 Director The Board maintains a standing Audit Committee comprised of Mr. ten Brink (Chairman), Mr. Schuler and Dr. Strobeck. The Board maintains a standing Compensation Committee comprised of Messrs. Miller, Patience, Schuler, Strobeck and ten Brink.
2017-04-10	Matthew W. Strobeck, Ph.D. 44 Director ...The Board maintains a standing Audit Committee comprised of Mr. ten Brink (Chairman), Mr. Schuler and Dr. Strobeck. ...The Board maintains a standing Compensation Committee comprised of Messrs. Miller, Patience, Schuler, Strobeck and ten Brink. ...The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2016: Matthew W. Strobeck, Ph.D. 79,519 79,519
2018-04-12	The Board maintains a standing Audit Committee comprised of Mr. ten Brink (Chairman), Mr. Schuler and Dr. Strobeck. Each member of the Audit Committee satisfies the independence standards specified in Rule 5605(a)(2) of the NASDAQ Listing Rules and the related rules of the SEC and has been determined by the Board to be “financially literate” with accounting or related financial management experience. The Board has also determined that Mr. ten Brink is an “audit committee financial expert” as defined under SEC rules and regulations, and qualifies as a financially sophisticated audit committee member as required under Rule 5605(c)(2)(A) of the NASDAQ Listing Rules. The Audit Committee has a written charter, a copy of which is available online at http://acceleratediagnostics.com/investors/corporate-governance/. The Audit Committee met 5 times during the year ended December 31, 2017. The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2017: Matthew W. Strobeck, Ph.D. Option Award(1) ($) 161,802 Total ($) 161,802
2019-04-05	Matthew W. Strobeck, Ph.D. has served as a Director of the Company since July 7, 2012. The Board maintains a standing Audit Committee comprised of Messrs. ten Brink (Chairman) and Miller and Dr. Strobeck. The members of the Compensation Committee during 2018 were Messrs. Brown, Strobeck, and Watts. The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2018: Matthew W. Strobeck, Ph.D. (8) 115,667(2) 115,667 As of December 31, 2018, Dr. Strobeck held 96,134 options to purchase shares of our common stock.
2020-04-01	Matthew W. Strobeck, Ph.D. has served as a Director of the Company since July 7, 2012. ... The Board maintains a standing Audit Committee comprised of Messrs. ten Brink (Chairman) and Miller and Dr. Strobeck. ... The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2019: Matthew W. Strobeck, Ph.D. (11) Option Award (1) ($) 133,904 Total ($) 133,904
2021-04-05	Matthew W. Strobeck, Ph.D. 48 Director... The Board has affirmatively determined that directors... Strobeck... are independent directors... The Board maintains a standing Audit Committee comprised of Messrs. ten Brink (Chairman) and Miller and Dr. Strobeck... The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2020: Matthew W. Strobeck, Ph.D. 58,254 58,254
2022-04-07	Matthew W. Strobeck, Ph.D. has served as a Director of the Company since July 7, 2012. ... The Board has affirmatively determined that directors ... Strobeck ... are “independent directors” ... The Board maintains a standing Audit Committee comprised of Messrs. ten Brink (Chairman), Burris, Miller and Dr. Strobeck. ... The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2021: Matthew W. Strobeck, Ph.D. 140,799
2023-05-01	Matthew W. Strobeck, Ph.D. has served as a Director of the Company since July 7, 2012... The following table sets forth the compensation of our directors for serving as our directors for the year ended December 31, 2022: Matthew W. Strobeck, Ph.D. 45,569